Evotec and Fraunhofer IME-SP sign strategic collaboration on iPSC technology

Evotec AG today announced a strategic collaboration on induced pluripotent stem cell („iPSC“) technology with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME, ScreeningPort. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-fraunhofer-ime-sp-sign-strategic-collaboration-on-ipsc-technology-5486

Weiterlesen

Ad hoc: Evotec AG to acquire Aptuit

Evotec AG today announced that it has entered into a definitive agreement with Aptuit Holdings LLC („Aptuit“) under which Evotec will acquire all operational business of Aptuit for $ 300 m (approx. EUR 256 m) to combine the businesses and expand Evotec’s role as leading player in integrated outsourced drug discovery and development solutions. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/ad-hoc-releases/p/ad-hoc-evotec-ag-to-acquire-aptuit-5

Weiterlesen

Evotec expands collaboration with STORM Therapeutics on its RNA epigenetic platform

Evotec AG announced today an integrated drug discovery collaboration with STORM Therapeutics („STORM“) to develop new small molecule epigenetic drugs for oncology and other therapeutic areas. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-collaboration-with-storm-therapeutics-on-its-rna-epigenetic-platform-5480

Weiterlesen

Evotec and Bayer advance endometriosis programme into Phase I clinical development and extend alliance

Evotec AG announced today that its multi-target endometriosis alliance with Bayer has advanced a programme from the alliance portfolio into Phase I clinical development for the treatment of endometriosis, triggering a milestone payment to Evotec. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-bayer-advance-endometriosis-programme-into-phase-i-clinical-development-and-extend-alliance-5478

Weiterlesen

Evotec received funding from IFB Hamburg to identify antibody-mediated t-cell immunotherapies

Evotec AG announced today that the Company has been awarded a ‚Programm für Innovation‘ („PROFI“) grant for a period of two years from the  Hamburgische Investitions- und Förderbank Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-received-funding-from-ifb-hamburg-to-identify-antibody-mediated-t-cell-immunotherapies-5476

Weiterlesen

Evotec expands iPSC drug discovery leadership through strategic collaboration with Censo Biotechnologies

Evotec AG today announced a collaboration with Censo Biotechnologies Ltd. („Censo“) to source and provide patient-derived induced pluripotent stem cells („iPSC“) to support Evotec’s broad iPSC platform. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-drug-discovery-leadership-through-strategic-collaboration-with-censo-biotechnologies-5474

Weiterlesen

Evotec announces strategic investment in Facio Therapies to support development of novel FSHD therapy

Evotec AG announced today that it will make a strategic investment as part of Facio Therapies‘ („Facio“) 2017 funding round together with Australian, European and North American members of the Facioscapulohumeral dystrophy („FSHD“) community (Total volume: EUR 4.8 m). Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-announces-strategic-investment-in-facio-therapies-to-support-development-of-novel-fshd-therapy-5470

Weiterlesen